FDA Approval Granted to Begin Clinical Trial KoDiscovery, LLC and NewG Lab Pharma, LLC have submitted the comprehensive IND (Investigational New Drug) application to the FDA for approval to begin a unique, combined Phase I/ II-A clinical trial for primary liver cancer.
Three New KOfactor 1 Advanced Products Are Now Available Dr. Ko has further enhanced the already potent KOfactor 1TM formulation by adding proprietary ratios of Resveratrol and Quercetin for even better results. Here is a little information you may find
Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA As of May 1, 2020, NewG Lab Pharma received a letter from the FDA for Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma”. As a result,
Acquired ODD status and License-In for additional Indications As of April 24, 2020, NewG Lab Pharma received the status of Orphan Drug Designation (ODD) for liver cancer and intrahepatic bile duct cancer from KoDiscovery. This acquisition of ODD status
Dietary supplement sales contract with KoDiscovery and Sales started in March NewG Lab Pharma, a 100% U.S. subsidiary of New G Lab, announced on February 14, 2020, that it has signed a KOfactor1 sales contract with KoDiscovery. KOfactor1, the first
Rak, nowe metaboliczne podejście (Polish version) By Travis Christofferson : How the Metabolic Theory of Cancer Is Overturning One of Medicine’s Most Entrenched Paradigms. Science writer Travis Christofferson illuminates a promising blend of old and new perspectives on the disease.
Cancer as a Metabolic Disease By Thomas Seyfried : On the Origin, Management, and Prevention of Cancer. The book addresses controversies related to the origins of cancer and provides solutions to cancer treatment and prevention. It expands Otto Warburg’s well-known
Tripping over the Truth By Travis Christofferson : How the Metabolic Theory of Cancer Is Overturning One of Medicine’s Most Entrenched Paradigms. Science writer Travis Christofferson illuminates a promising blend of old and new perspectives on the disease. Tripping over
-Yvar Verhoeven meets students after his presentation at John’s Hopkins, November 13th, 2009. -The first patient to be treated with Dr. Ko’s 3BP compound. -A Translational Study “Case Report” on the Small Molecule “Energy Blocker” 3-Bromopyruvate (3BP) as a Potent
NCI and NIH Mitochondria Interest Group Seminar: Johns Hopkins’ Pedersen Addresses Role of Mitochondria in Cancer https://videocast.nih.gov/summary.asp?live=7542&bhcp=1